Get notified of page updates

Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. You can do a quick search to filter our featured studies by cancer type, study type or key word, or a more in-depth search through clinicaltrials.gov.

How to Use Our Search and Enroll Tool

Search Results: Treatment + Prostate Cancer + Hormone Sensitive (0 results)

Additional Results on Clinicaltrials.gov Treatment + Prostate Cancer + Hormone Sensitive + adt
58 results
Clinical Trial Official Title
NCT04748042 Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
NCT06397703 ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
NCT05628363 Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
NCT05477823 Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
NCT05361798 T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy
NCT04465500 EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
NCT06212583 High-Risk Metachronous Oligometastatic Prostate Cancer Trial
NCT06369610 Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer
NCT04947254 Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
NCT06244004 FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
NCT05169970 A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
NCT04349501 Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
NCT01985828 CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
NCT05838716 High-Dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
NCT04402151 Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
NCT04943536 Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
NCT03553602 BEACON: HDR Brachytherapy, EBRT and STAD for the Treatment of Local and Pelvic Recurrence of Prostate Cancer After Radiation Therapy
NCT05155046 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
NCT05568550 Pembro With Radiation With or Without Olaparib
NCT05726292 A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
NCT06111781 The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer
NCT05320406 RElugolix VErsus LeUprolide Cardiac Trial
NCT04025372 INTREPId (INTermediate Risk Erection PreservatIon Trial)
NCT05915442 Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
NCT04019964 Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
NCT03456843 Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer
NCT05053152 Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer
NCT06205316 SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
NCT04734730 Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
NCT05765500 RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
NCT04725903 Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
NCT04705038 Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments
NCT04633252 M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
NCT06347705 A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
NCT05939414 An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05133440 A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones
NCT04787744 Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT05050084 Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
NCT04704505 Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06044857 PSMA PET Response Guided SabR in High Risk Pca
NCT04116775 Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
NCT04513717 Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT02040610 Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer
NCT05700903 Contributions to Hypertension With Androgen Deprivation Therapy
NCT06305598 Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
NCT04423211 Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04666129 Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
NCT05617040 Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
NCT04363164 Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
NCT05348577 Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT04175431 Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
NCT04253483 Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
NCT05946213 Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT06039371 Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
NCT06059118 Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
NCT04421222 Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer
NCT04188535 Serial MRI Scans During Radiation Therapy
NCT05498272 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations

Research Search Tool Sponsored By: